Opendata, web and dolomites

GlyCan

Innovative Glycan-based analysis for Cancer diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlyCan project word cloud

Explore the words cloud of the GlyCan project. It provides you a very rough idea of what is the project "GlyCan" about.

prior    biomarkers    biopsies    launched    lacks    glycanostics    pca    combined    kit    examinations    undergo    throughput    diagnostic    needless    sending    worldwide    consists    mrna    advantage    biopsy    simplicity    outcome    screening    check    core    clinically    74    deaths    competitive    ing    patent    discriminates    annually    representing    positive    antigen    b2b    rectal    confirm    6m    311532    competitors    tkac    2nd    accuracy    clinics    dre    economic    examination    patients    innovative    hospital    serum    grant    sick    business    invasive    suspicious    home    circulating    proteins    dr    instead    advisors    owned    75    founder    glycan    dx    digital    preliminary    members    prostate    jan    pain    homes    accurately    b2c    biomarker    granted    quantifying    centres    rate    366k    opinion    detect    societal    biomolecules    psa    assay    dna    protein    cso    erc    team    company    blood    burden    healthy    covered    quantify    market    mistreatment    commercial    scientific    cancer    epo    diagnostics    co    95    false   

Project "GlyCan" data sheet

The following table provides information about the project.

Coordinator
GLYCANOSTICS SRO 

Organization address
address: DUBRAVSKA CESTA 9
city: BRATISLAVA
postcode: 845 38
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Slovakia [SK]
 Project website https://www.glycanostics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCANOSTICS SRO SK (BRATISLAVA) coordinator 50˙000.00

Map

 Project objective

Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually. Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients. The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for preliminary screening. If the combined results are suspicious, the patients undergo a biopsy to confirm PCa. Yet, there are 74% of needless biopsies representing a significant pain for PCa patients and societal/economic burden.

Based on a great commercial outcome from the ERC grant (311532) granted to Dr. Jan Tkac (co-founder/CSO of Glycanostics), the company has developed an innovative, non-invasive, early PCa diagnostics using blood serum. Instead of quantifying PSA, the innovative PCa diagnostic assay detect glycan changes on PSA protein (it discriminates between “healthy” PSA and “sick” PSA and accurately quantify the clinically relevant “sick” PSA). The technology is covered by two EPO patent applications owned by the company. The PCa diagnostic test with 95% accuracy will be applied as a 2nd opinion test in case of suspicious results from PSA & DRE examinations prior sending to a biopsy. PCa DX kit will be launched for clinics/hospital & cancer centres (B2B) and Prostate check home test for user-friendly application at homes (B2C).

Our PCa diagnostic technology is unique compared to our competitors focusing on analysis of other complex biomolecules such as a level of proteins, mRNA and circulating DNA. Moreover, we have competitive advantage over competitors in terms of cost per sample, assay accuracy, simplicity of the assay enabling the home testing and high-throughput.

Glycanostics consists of 7 core team members, 4 business and 4 scientific advisors making a great and highly experienced team that will bring these innovative PCa early diagnostic products to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More  

Genetta (2019)

Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbing

Read More